SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $689,000 | -28.9% | 12,128 | -6.4% | 0.24% | +60.0% |
| Q1 2021 | $969,000 | -45.7% | 12,952 | -37.2% | 0.15% | -40.7% |
| Q4 2020 | $1,786,000 | +16.7% | 20,640 | -17.6% | 0.25% | -5.2% |
| Q3 2020 | $1,531,000 | +59.6% | 25,044 | +8.6% | 0.27% | +41.3% |
| Q2 2020 | $959,000 | +123.0% | 23,055 | +54.1% | 0.19% | -46.3% |
| Q1 2020 | $430,000 | -70.0% | 14,961 | -24.7% | 0.35% | +66.8% |
| Q4 2019 | $1,434,000 | +329.3% | 19,867 | +733.3% | 0.21% | +174.0% |
| Q3 2019 | $334,000 | -39.7% | 2,384 | -21.3% | 0.08% | -26.0% |
| Q2 2019 | $554,000 | +57.8% | 3,028 | +21.8% | 0.10% | +55.2% |
| Q3 2018 | $351,000 | +57.4% | 2,486 | -44.2% | 0.07% | -26.4% |
| Q4 2016 | $223,000 | -0.4% | 4,457 | -9.2% | 0.09% | +11.0% |
| Q3 2016 | $224,000 | -1.8% | 4,908 | -32.6% | 0.08% | -6.8% |
| Q1 2016 | $228,000 | -25.0% | 7,280 | +40.1% | 0.09% | +7.3% |
| Q4 2015 | $304,000 | -27.3% | 5,197 | -47.4% | 0.08% | -60.2% |
| Q3 2015 | $418,000 | – | 9,889 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |